Skip to search formSkip to main contentSkip to account menu
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
TLDR
Deprenyl but not tocopherol delays the onset of disability associated with early, otherwise untreated Parkinson's disease and the action of deprenyl that accounts for its beneficial effects remains unclear.
View on PubMed
Neuropsychiatric symptoms in Parkinson's disease
  • J. Friedman
  • Psychology, Medicine
    Movement disorders : official journal of the…
  • 1 January 2011
In their excellent review of neuropsychiatric problems in Parkinson’s disease (PD), the authors made one small error but more importantly raised an interesting question about drug trials. Also, as…
View on Wiley
Fatigue in Parkinson's disease: A review
TLDR
What is known about fatigue in Parkinson's disease is reviewed, putting it into the context of fatigue in other disorders, and a program for developing better understanding and therapy is outlined.
View on Wiley
Effect of deprenyl on the progression of disability in early Parkinson's disease.
TLDR
It is concluded from these preliminary results that the use of deprenyl (10 mg per day) delays the onset of disability associated with early, otherwise untreated cases of Parkinson's disease.
View on PubMed
Effects of fatigue on physical activity and function in patients with Parkinson’s disease
TLDR
PD patients with more severe fatigue are more sedentary and have poorer functional capacity and physical function compared with patients with less fatigue, and the Up and Go Test, Leisure Activity Score, CL use, and diastolic blood pressure were the best predictor variables of fatigue.
View on Wolters Kluwer
Political Correctness.
View on PubMed
Scales to assess psychosis in Parkinson's disease: Critique and recommendations
TLDR
None of the current scales contained all the basic content, mechanistic and psychometric properties needed to capture PD psychotic phenomena and to measure clinical response over time.
View on Wiley
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease
TLDR
A task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies inPD concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.
View on Wiley
Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease
  • J. Friedman, S. Factor
  • Psychology, Medicine
    Movement disorders : official journal of the…
  • 1 March 2000
TLDR
The only drug with confirmed benefit without worsening parkinsonism is clozapine and it is recommended that DP be treated in the following manner: first, the anti-PD medications should be simplified and reduced as much as tolerated, and secondly, levodopa is reduced.
View on Wiley
Ophthalmologic features of Parkinson's disease.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License